Dev4All Joins Forces With Pharmaseed For Preclinical Innovation

Dev4All, the innovative R&D accelerator from 4P-Pharma, has announced a strategic partnership with Pharmaseed, a leading Contract Research Organization (CRO) with over two decades of expertise in preclinical drug development. The goal of this collaboration is to enhance preclinical processes by combining both entities' strengths to provide an integrated, end-to-end solution for drug development.

Revital Rattenbach, Executive Chair of Dev4All, said in a statement, “I am thrilled about the new collaboration between Dev4All and Pharmaseed, which marks an exciting step forward in our shared commitment to innovation. This commercial cooperation empowers us to scale our capabilities, elevate our global impact, and deliver tailor-made solutions that meet our client’s needs while maintaining the highest standards of scientific rigour.” 

The partnership leverages Pharmaseed's extensive experience in CRO services and Dev4All's expertise in advancing drug candidates through Technology Readiness Levels (TRLs) 3 to 5. Together, the organisations will deliver tailored preclinical support, cutting-edge laboratory resources, and strategic guidance to accelerate drug development and navigate the complexities of modern R&D challenges.

“This collaboration with Dev4All is an excellent opportunity to expand our European presence and integrate our comprehensive preclinical solutions with the DEV4ALL innovative R&D platform. Together, we are committed to delivering top-tier services and ensuring clients achieve their scientific and clinical milestones,” stated Shmuel Landau, Co-CEO of Pharmaseed.

Dev4All and Pharmaseed combine resources and capabilities to provide comprehensive and competitive preclinical solutions. This enables worldwide clients to optimise their research and development efforts.